Imipramine Pamoate
This pamoate salt of imipramine provides extended-release characteristics suitable for once-daily dosing in the treatment of depression and anxiety. The pamoate salt reduces gastrointestinal side effects and provides sustained drug levels throughout the day. Like other imipramine formulations, it inhibits neurotransmitter reuptake and carries the same cautions regarding cardiac and anticholinergic effects.
Berat Molekul
949,2000 g/mol
TPSA
128,00 Ų
Area Terapeutik
Mekanisme Kerja
Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.
Struktur 2D
Cite this structure
Embed this structure
SMILES
CN(C)CCCN1c2ccccc2CCc2ccccc21.CN(C)CCCN1c2ccccc2CCc2ccccc21.O=C(O)c1cc2ccccc2c(Cc2c(O)c(C(=O)O)cc3ccccc23)c1O
InChI
InChI=1S/C23H16O6.2C19H24N2/c24-20-16(14-7-3-1-5-12(14)9-18(20)22(26)27)11-17-15-8-4-2-6-13(15)10-19(21(17)25)23(28)29;2*1-20(2)14-7-15-21-18-10-5-3-8-16(18)12-13-17-9-4-6-11-19(17)21/h1-10,24-25H,11H2,(H,26,27)(H,28,29);2*3-6,8-11H,7,12-15H2,1-2H3
Molecular Formula
C61H64N4O6
HBD / HBA
4 / 10
Ikatan yang Dapat Dirotasi
12
Atom Berat
71
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Pertanyaan yang Sering Diajukan
This pamoate salt of imipramine provides extended-release characteristics suitable for once-daily dosing in the treatment of depression and anxiety. The pamoate salt reduces gastrointestinal side effects and provides sustained drug levels throughout the day. Like other imipramine formulations, it inhibits neurotransmitter reuptake and carries the same cautions regarding cardiac and anticholinergic effects.
Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.
Yes, Imipramine Pamoate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3989845. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 24904. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="imipramine-pamoate"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/imipramine-pamoate/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/imipramine-pamoate/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/imipramine-pamoate/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="imipramine-pamoate"></drugfyi-drug>